

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Larotrectinib for treating NTRK fusion-positive advanced solid tumours (Managed access review of TA630) [ID6292]


Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Bayer (larotrectinib)	All Wales Therapeutics and Toxicology
Patient/carer groups	Centre Allied Health Professionals Federation
Action Kidney Cancer	Board of Community Health Councils in
Anthony Pilcher Bone Cancer Trust	Wales
Asthma + Lung Foundation	British National Formulary
Black Health Agency for Equality	Care Quality Commission
Bob Champion Cancer Trust	Department of Health - Northern Ireland
Bowel Cancer UK	Healthcare Improvement Scotland
Breast Cancer Now	Medicines and Healthcare products
Breast Cancer UK	Regulatory Agency
British Skin Foundation British Skin Foundation British Skin Foundation British Skin Foundation	National Association of Primary Care National Pharmany Association
Butterfly Thyroid Cancer Trust	National Pharmacy AssociationNHS Confederation
Cancer 52Cancer Black Care	NHS Wales Joint Commissioning
Cancer Black CareCancer Laryngectomee Trust	Committee
Changing Faces	Scottish Medicines Consortium
Childhood Cancer Parents Alliance	Welsh Government
Children's Cancer and Leukaemia	
Group	Possible comparator companies
Children with Cancer	None
Genetic Alliance UK	Delever the second surviva
Get-A-Head	Relevant research groups
GIST Support UK	Against Breast CancerBone Cancer Research Trust
Helen Rollason Cancer Charity	Bone Research Society
Independent Cancer Patients Voice Kide and Cancer Patients Voice Market Patients Market Patien	Breast Cancer Hope
Kidney Care UK Kidney Care UK	Breast Cancer Research Trust
Kidney Care UKKidney Research UK	Cochrane Breast Cancer Group
Let's Face It	Cochrane Childhood Cancer Group
Macmillan Cancer Support	Cochrane Lung Cancer Group
Maggie's Centres	Cochrane Prostatic Diseases Urologic
Marie Curie	Cancers Group
Mouth Cancer Foundation	Cochrane Skin Group
	Genomics England

Provisional stakeholder list for the evaluation of larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]



Provisional Consultees Provisional Commentators (no right to submit or appeal) National Association of Head and Neck Cancer Research Trust Laryngectomee Clubs Institute of Cancer Research National Kidney Federation Melanoma Fund Orchid - Fighting Male Cancer MRC Clinical Trials Unit Prostate Cancer UK National Institute for Health Research Roy Castle Lung Cancer Foundation Pro Cancer Research Fund Sarcoma UK Prostate Cancer Research Centre Solving Kid's Cancer Research Institute for the Care of Older South Asian Health Foundation Specialised Healthcare Alliance Skin Cancer Research Fund Swallows Head and Neck Cancer Skin Treatment & Research Trust Support Group Teenage Cancer Trust Associated Public Health groups **Public Health Wales Tenovus Cancer Care** UK Health Security Agency Together for Short Lives **UK Lung Cancer Coalition** Women's Health Concern Young Lives vs Cancer Professional groups Association of Anaesthetists Association of Cancer Physicians Association of Respiratory Nurse **Specialists** Association of Surgeons of Great Britain and Ireland **British Association of Dermatologists** British Association of Endocrine and Thyroid Surgeons British Association of Skin Cancer **Specialist Nurses British Association of Surgical** Oncology British Association of Urological Surgeons British Dermatological Nursing Group **British Geriatrics Society** British Institute of Radiology **British Oncology Pharmacy** Association **British Orthopaedic Association** British Orthopaedic Oncology Society British Psychosocial Oncology Society British Sarcoma Group




Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Society for Dermatological Surgery British Society of Skeletal Radiologists British Society of Urogenital Radiology British Thoracic Oncology Group British Thoracic Society British Thyroid Association British Uro-oncology Group Cancer Research UK CCLG: The Children & Young People's Cancer Association Lung Cancer Nursing UK Melanoma Focus Pelican Cancer Foundation Primary Care Dermatology Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Kidney Association UK Oncology Nursing Society UK Renal Pharmacy Group 	
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the

Provisional stakeholder list for the evaluation of larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]



evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.